AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18242724 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 18242724 — intervention group
Group type: COMPARATOR
Intervention: Untreated migraineurs
Number of subjects: 0
Study 16828095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (25 mug every 6 hours)
Number of subjects: 150
Study 16828095 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (25 mug every 6 hours)
Number of subjects: 150
Study 12681024 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tablet metformin-glibenclamide combination therapy (Glucovance®)
Number of subjects: 1856
Study 12681024 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg and glibenclamide 2.5‐5 mg monotherapy
Number of subjects: 1856
Study 11015699 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical probability presentation (e.g. 1:650 chance)
Number of subjects: 220
Study 11015699 — intervention group
Group type: COMPARATOR
Intervention: Verbal probability presentation (e.g. 'your chance is low')
Number of subjects: 220
Study 11015699 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical probability presentation
Number of subjects: 220
Study 11015699 — intervention group
Group type: COMPARATOR
Intervention: Verbal probability presentation
Number of subjects: 220
Study 1452619 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of timolol (oral administration)
Number of subjects: 0
Study 1452619 — intervention group
Group type: COMPARATOR
Intervention: Propranolol as internal standard
Number of subjects: 0
Study 3867354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 150 mg
Number of subjects: 0
Study 3867354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 300 mg
Number of subjects: 0
Study 3867354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine (single and 14-day regimens)
Number of subjects: 0
Study 31371810 — intervention group
Group type: EXPERIMENTAL
Intervention: Miso group (32 g 2:1 w/w Nenrin and MK‐34‐1 with 3.8 g salt/day)
Number of subjects: 40
Study 31371810 — intervention group
Group type: COMPARATOR
Intervention: Control soy food group (14.4 g soy food with 0.2 g salt/day)
Number of subjects: 40
Study 29431535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy breakfast (205 kcal)
Number of subjects: 16
Study 29431535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy breakfast (570 kcal)
Number of subjects: 16
Study 29431535 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participants
Number of subjects: 16
Study 29431535 — intervention group
Group type: COMPARATOR
Intervention: Differences in postprandial insulin between breakfasts
Number of subjects: 16
Study 27406142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IP) - 4 × 5 min 220 mmHg bilateral upper leg occlusion
Number of subjects: 11
Study 27406142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IP)
Number of subjects: 11
Study 27406142 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - 4 × 5 min 50 mmHg bilateral occlusion
Number of subjects: 11
Study 27406142 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 11
Study 25417983 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicarious error management training
Number of subjects: 22
Study 25417983 — intervention group
Group type: COMPARATOR
Intervention: Traditional procedural-based instruction
Number of subjects: 22
Study 22621799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine plus amiodarone (group A + R)
Number of subjects: 51
Study 22621799 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone alone (group A)
Number of subjects: 51
Study 19834635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous hysteropexy
Number of subjects: 66
Study 19834635 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 66
Study 17511759 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL, 8 infusions at 4 mg during the first 12 months after LT), calcium (1000 mg/d), and vitamin D (800 IE/d)
Number of subjects: 96
Study 17511759 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1000 mg/d) and vitamin D (800 IE/d)
Number of subjects: 96
Study 17511759 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 96
Study 15660089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (Salagen) tablets, escalating doses of 2.5 mg to 5 mg or 5 mg to 7.5 mg qid for 6 weeks, followed by placebo qid for a 2-week washout period
Number of subjects: 28
Study 15660089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12501875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 32
Study 12501875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10070908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ramipril (1.25 mg orally once daily)
Number of subjects: 13
Study 10070908 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ramipril (10 mg orally once daily)
Number of subjects: 13
Study 10070908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7585845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime 1 g IM once daily (group A)
Number of subjects: 298
Study 7585845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime 1 g IM twice daily (group B)
Number of subjects: 298
Study 7585845 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g IM once daily (group C)
Number of subjects: 298
Study 2178391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose preload
Number of subjects: 0
Study 2178391 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame preload
Number of subjects: 0
Study 2178391 — intervention group
Group type: COMPARATOR
Intervention: Plain water control
Number of subjects: 0
Study 2178391 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose preload
Number of subjects: 0
Study 261517 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally applied hog pancreatic kallikrein
Number of subjects: 67
Study 261517 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive subjects on low sodium diet)
Number of subjects: 67
Study 261517 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with borderline hypertension on low sodium diet)
Number of subjects: 67
Study 261517 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with sustained hypertension on low sodium diet)
Number of subjects: 67
Study 29790804 — intervention group
Group type: EXPERIMENTAL
Intervention: Wartner (cryotherapy compound containing dimethyl ether 75% and propane 25%)
Number of subjects: 16
Study 29790804 — intervention group
Group type: COMPARATOR
Intervention: Liquid nitrogen (control)
Number of subjects: 16
Study 28851320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 80
Study 28851320 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 80
Study 25897762 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered care planning intervention involving intensive staff training and 12 months of ongoing technical assistance.
Number of subjects: 280
Study 25897762 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 280
Study 23410994 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills to fuel the body lesson, goal setting, and research snippets
Number of subjects: 653
Study 23410994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lessons on body size and eating enjoyment, and suggested weekly activities
Number of subjects: 653
Study 21466991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (2-4%)
Number of subjects: 40
Study 21466991 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (1-2%)
Number of subjects: 40
Study 19736898 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (1 mg bolus followed by 1 mg h(‐1))
Number of subjects: 80
Study 19736898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v. saline)
Number of subjects: 80
Study 18177192 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons' subjective evaluations of facial form for the need for lip revision surgery
Number of subjects: 21
Study 18177192 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons' recommendations for revision based on prerevision and postrevision views
Number of subjects: 21
Study 15030537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis with acetate solution
Number of subjects: 63
Study 15030537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis with bicarbonate solution
Number of subjects: 63
Study 15030537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DH
Number of subjects: 63
Study 15030537 — intervention group
Group type: COMPARATOR
Intervention: Patients without DH
Number of subjects: 63
Study 15030537 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 63
Study 11486253 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg titrated to 300 mg)
Number of subjects: 52
Study 10687337 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate and dextromethorphan hydrobromide (MS:DM)
Number of subjects: 0
Study 10687337 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate (MS) alone
Number of subjects: 0
Study 8721977 — intervention group
Group type: EXPERIMENTAL
Intervention: CYCLO 3 FORT
Number of subjects: 57
Study 8721977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 1992551 — intervention group
Group type: EXPERIMENTAL
Intervention: DL‐3‐hydroxybutyrate (3‐OHB) at a rate of 25 mumol/kg/min for 3 hours
Number of subjects: 20
Study 1992551 — intervention group
Group type: COMPARATOR
Intervention: Sodium DL‐lactate at the same rate as the control subjects
Number of subjects: 20
Study 6882809 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-relax (WR)
Number of subjects: 16
Study 6882809 — intervention group
Group type: COMPARATOR
Intervention: Cool-relax (CR)
Number of subjects: 16
Study 30677175 — intervention group
Group type: EXPERIMENTAL
Intervention: Beyond Good Intentions (BGI) self-management programme
Number of subjects: 108
Study 30677175 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 108
Study 29305456 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap irrigation solution
Number of subjects: 0
Study 29305456 — intervention group
Group type: COMPARATOR
Intervention: Normal saline irrigation solution
Number of subjects: 0
Study 29305456 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low irrigation pressure
Number of subjects: 0
Study 29305456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low irrigation pressure
Number of subjects: 0
Study 29305456 — intervention group
Group type: EXPERIMENTAL
Intervention: High irrigation pressure
Number of subjects: 0
Study 26315303 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate containing 50 mg zinc) for 8 weeks
Number of subjects: 48
Study 26315303 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 48
Study 24393852 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib at 50 mg/m², administered as a 2-hour infusion every 21 days
Number of subjects: 30
Study 24393852 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine at 1250 mg/m², administered orally twice daily in 21-day cycles
Number of subjects: 30
Study 22668798 — intervention group
Group type: EXPERIMENTAL
Intervention: LPD 7/7
Number of subjects: 38
Study 22668798 — intervention group
Group type: COMPARATOR
Intervention: LPD 6/7
Number of subjects: 38
Study 20842129 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF (docetaxel, cisplatin, 5-fluorouracil)
Number of subjects: 358
Study 20842129 — intervention group
Group type: COMPARATOR
Intervention: PF (cisplatin, 5-fluorouracil)
Number of subjects: 358
Study 17490968 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplementation (60,000 microg to mothers and 7500 microg to infants)
Number of subjects: 780
Study 17490968 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose vitamin A supplementation (60,000 microg to mothers and 15,000 microg to infants)
Number of subjects: 780
Study 16170938 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch screen
Number of subjects: 120
Study 16170938 — intervention group
Group type: COMPARATOR
Intervention: Rotary encoder
Number of subjects: 120
Study 11823395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 10
Study 11823395 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.5%
Number of subjects: 10
Study 10651974 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase therapy (Pulmozyme(R)) over a 6-month period
Number of subjects: 1
Study 10651974 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase therapy
Number of subjects: 1
Study 10651974 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase therapy for subgroup of patients with moderate lung disease
Number of subjects: 1
Study 10651974 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase therapy for subgroup of patients
Number of subjects: 1
Study 7675044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-index group
Number of subjects: 762
Study 7675044 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-saturation group
Number of subjects: 762
Study 7675044 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 762
Study 7675044 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis (targets reached) - Cardiac-index group
Number of subjects: 762
Study 7675044 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis (targets reached) - Oxygen-saturation group
Number of subjects: 762
Study 7675044 — intervention group
Group type: COMPARATOR
Intervention: Subgroup analysis (targets reached) - Control group
Number of subjects: 762
Study 2147637 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate 400 mg day‐1
Number of subjects: 36
Study 31258137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day clear liquid diet (CLD) + polyethylene glycol and electrolyte lavage solution (PEG-ELS)
Number of subjects: 506
Study 31258137 — intervention group
Group type: COMPARATOR
Intervention: 3-day combined diet (CMD) + polyethylene glycol and electrolyte lavage solution (PEG-ELS)
Number of subjects: 506
Study 31258137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day clear liquid diet (CLD) + sulfate free polyethylene glycol and electrolyte lavage solution (SF-PEG-ELS)
Number of subjects: 506
Study 31258137 — intervention group
Group type: COMPARATOR
Intervention: 3-day combined diet (CMD) + sulfate free polyethylene glycol and electrolyte lavage solution (SF-PEG-ELS)
Number of subjects: 506
Study 31258137 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 506
Study 31258137 — intervention group
Group type: COMPARATOR
Intervention: SF-PEG-ELS users
Number of subjects: 506
Study 30092197 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-spectrum antibiotics (vancomycin)
Number of subjects: 63
Study 30092197 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (oral vancomycin, ciprofloxacin, metronidazole)
Number of subjects: 63
Study 30092197 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (control)
Number of subjects: 63
Study 30092197 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 63
Study 26946732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting pricking, cupping, and surrounding acupuncture treatment, given once a day and once every other day after the first 3 days for a total of one week.
Number of subjects: 60
Study 26946732 — intervention group
Group type: COMPARATOR
Intervention: Intravenous drip of acyclovir and oral administration of vitamin B1 and B12, once a day for a total of one week.
Number of subjects: 60
Study 24145204 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level intervention including fundamental movement skill sessions, structured activities, staff role modelling, limiting small screen recreation and sedentary time, and an activity promoting physical environment.
Number of subjects: 459
Study 24145204 — intervention group
Group type: COMPARATOR
Intervention: Control group continued with usual routines.
Number of subjects: 459
Study 24145204 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level intervention
Number of subjects: 459
Study 22763905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL/kg acetated Ringer's solution
Number of subjects: 10
Study 22763905 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/kg acetated Ringer's solution
Number of subjects: 10
Study 22763905 — intervention group
Group type: COMPARATOR
Intervention: Dehydration
Number of subjects: 10
Study 21378348 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (50 mg)
Number of subjects: 12
Study 21378348 — intervention group
Group type: COMPARATOR
Intervention: FT (800 mg)
Number of subjects: 12
Study 21378348 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (b.i.d. for 14 days)
Number of subjects: 12
Study 21378348 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 12
Study 17389005 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed oral 17beta‐estradiol
Number of subjects: 186
Study 17389005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 16277792 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-supplemented diet (35 g daily)
Number of subjects: 90
Study 16277792 — intervention group
Group type: COMPARATOR
Intervention: Control diet (no walnuts)
Number of subjects: 90
Study 11865838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF)
Number of subjects: 120
Study 11865838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10445898 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management and subsidized community services
Number of subjects: 8095
Study 10445898 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8095
Study 7601294 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytic (fludiazepam) for 12 weeks
Number of subjects: 20
Study 2088109 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml mixture including 3 ml of 0.5% bupivacaine, 0.2 mg adrenaline
Number of subjects: 20
Study 2088109 — intervention group
Group type: COMPARATOR
Intervention: 4 ml mixture including 3 ml of 0.5% bupivacaine, 0.15 mg clonidine
Number of subjects: 20
Study 440849 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestant-antihistamine mixture
Number of subjects: 104
Study 440849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 31530561 — intervention group
Group type: EXPERIMENTAL
Intervention: iBox risk prediction score
Number of subjects: 7557
Study 28602694 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged targeted temperature management (TTM) at 33±1°C for 48 hours
Number of subjects: 82
Study 28602694 — intervention group
Group type: COMPARATOR
Intervention: Standard targeted temperature management (TTM) at 33±1°C for 24 hours
Number of subjects: 82
Study 25254938 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg tamsulosin and 50 mg mirabegron daily for 8 weeks
Number of subjects: 94
Study 25254938 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg tamsulosin daily for 8 weeks
Number of subjects: 94
Study 23388051 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured cue to highlight written infectious status information in the transfer form
Number of subjects: 300
Study 23388051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transfer checklist used by radiology porters
Number of subjects: 300
Study 23388051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions applied (coloured cue and pre-transfer checklist)
Number of subjects: 300
Study 23388051 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 300
Study 21503605 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol at 0.04% BAC
Number of subjects: 96
Study 21503605 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol at 0.075% BAC
Number of subjects: 96
Study 21503605 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol at 0.11% BAC
Number of subjects: 96
Study 21503605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 21503605 — intervention group
Group type: EXPERIMENTAL
Intervention: High threat intensity
Number of subjects: 96
Study 21503605 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/low threat intensity
Number of subjects: 96
Study 21503605 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier, more problematic drinkers
Number of subjects: 96
Study 19484846 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Care Management (DCM) intervention
Number of subjects: 0
Study 19484846 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study 16418054 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors judging speakers with acquired dysarthria
Number of subjects: 0
Study 16418054 — intervention group
Group type: COMPARATOR
Intervention: Controls (matched for age and gender with neurological deficits not affecting speech)
Number of subjects: 0
Study 12915681 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg/d)
Number of subjects: 18
Study 12915681 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/d)
Number of subjects: 18
Study 12915681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined candesartan/spironolactone
Number of subjects: 18
Study 12915681 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (20 mg/d)
Number of subjects: 18
Study 10596522 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (GCBT) with concurrent parent sessions
Number of subjects: 0
Study 10596522 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC) condition
Number of subjects: 0
Study 8735854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms once daily
Number of subjects: 0
Study 8735854 — intervention group
Group type: COMPARATOR
Intervention: Oral fluticasone propionate 5 mg or 10 mg once daily
Number of subjects: 0